Transcept Pharmaceuticals Inc·4

Jul 18, 6:11 PM ET

Transcept Pharmaceuticals Inc 4

4 · Transcept Pharmaceuticals Inc · Filed Jul 18, 2013

Insider Transaction Report

Form 4
Period: 2013-07-15
OCLASSEN GLENN A
DirectorPresident and CEO
Transactions
  • Award

    Common Stock Option (right to buy)

    2013-07-15+225,000225,000 total
    Exercise: $2.93Exp: 2023-07-15Common Stock (225,000 underlying)
Footnotes (1)
  • [F1]The option vests in forty-eight equal monthly installments beginning on August 15, 2013.

Documents

1 file
  • 4
    rrd386005.xmlPrimary

    FORM 4 - OCLASSEN